Institut Des Neurosciences De La Timone

At Institut Des Neurosciences De La Timone, a major share of the research focuses on neoplasms, with studies spanning advanced solid tumors, melanoma, metastatic melanoma, soft tissue sarcoma, hepatocellular carcinoma, and non-Hodgkin lymphoma. These trials are designed to test new treatment strategies, refine adjuvant therapy, and assess whether targeted or immune-based approaches can improve outcomes for patients with difficult-to-treat cancers.

• Testing immunotherapy combinations and other novel anticancer treatments for recurrent or metastatic disease
• Evaluating adjuvant approaches after surgery to reduce relapse risk in high-risk cancer patients
• Exploring precision medicine strategies for tumors with specific molecular features or histology

This oncology portfolio reflects a strong interest in both treatment effectiveness and safer, more personalized care for patients with complex cancers.

Research in nervous system diseases includes studies in multiple sclerosis, acute ischemic stroke, and KCNT1-related developmental and epileptic encephalopathy. The clinical trials in this area aim to improve symptom control, protect neurological function, and evaluate long-term safety and effectiveness of therapies used in children and adults.

• Assessing treatments for pediatric multiple sclerosis and their impact on long-term health
• Studying interventions for acute stroke to improve recovery after reperfusion treatment
• Evaluating safety and tolerability in rare pediatric epilepsy syndromes

This work combines common neurological conditions with rare disorders, showing a broad commitment to advancing care across the field of neurology.

The site also supports trials in cardiovascular diseases, including acute myocarditis and acute ischemic stroke. These studies are focused on improving diagnosis, reducing tissue injury, and testing whether existing or new treatments can lead to better clinical outcomes in urgent settings.

• Evaluating therapies that may limit heart inflammation and related damage
• Testing treatment strategies to improve functional recovery after stroke
• Using imaging and clinical follow-up to better understand disease progression

This area highlights the center’s interest in fast-moving conditions where early treatment decisions can strongly influence patient recovery.

Within hormonal diseases, the trials include pancreatic well differentiated neuroendocrine tumors and uterine leiomyosarcoma. These studies are aimed at improving disease control after surgery, testing the value of additional therapy, and identifying patients most likely to benefit from specific treatment approaches.

• Studying adjuvant treatment to lower recurrence risk after tumor removal
• Comparing treatment approaches in rare endocrine-related cancers
• Evaluating effectiveness in patients with high-risk tumor profiles

The research in this field emphasizes careful treatment selection for uncommon cancers where better evidence is still needed.

A smaller but important part of the program covers analytical, diagnostic and therapeutic techniques and equipment, with studies that use imaging, biomarker testing, and other tools to guide treatment decisions. At this laboratory and research facility in Marseille, these efforts help determine how well new tests and clinical measures can support more accurate diagnosis and treatment monitoring.

• Improving disease assessment through imaging-based and laboratory-supported methods
• Using biomarkers to identify patients at higher risk of relapse or progression
• Supporting treatment planning with more precise diagnostic information

This research strengthens the link between diagnosis and therapy, especially in complex diseases where better patient selection can improve care.